MAP2K7 and Miyoshi myopathy: As a result of this therapeutic mode of action, DTP3 specifically kills MM cells exhibiting elevated GADD454β expression, ex vivo and in vivo, by inducing MKK7/JNK-driven apoptosis, and, importantly, does not appear to be toxic to normal tissues.